F. Callea et al., ALPHA(1)-ANTITRYPSIN (AAT) DEFICIENCY AND ANCA-POSITIVE SYSTEMIC VASCULITIS - GENETIC AND CLINICAL IMPLICATIONS, European journal of clinical investigation, 27(8), 1997, pp. 696-702
Citations number
23
Categorie Soggetti
Medicine, Research & Experimental","Medicine, General & Internal
A high incidence of alpha(1)-antitrypsin (AAT) deficiency has been rep
orted in patients with C-ANCA systemic vasculitis in association with
antibodies against proteinase-3 (PR3). To clarify the role of AAT defi
ciency in the acute vasculitic process as well as in progression of th
e disease, we studied 84 patients with either C-ANCA or P-ANCA vasculi
tis with special reference to: (a) the AAT gene, (b) the phenotypic (P
i) variants and (c) the serum levels during both acute illness and rem
ission. The PiZ gene was found in six patients (8% vs. 1.5% controls)
irrespective of the type of autoantibodies (C-ANCA vs. P-ANCA). All Pi
Z patients displayed the ability to raise their AAT serum levels up to
the normal range during acute illness. In contrast, 24 patients with
the PiM phenotype presented low AAT serum levels during acute illness.
In all these patients, the AAT levels returned to normal values durin
g the remission. Low AAT levels were associated with low levels of C-r
eactive protein (PCR) (P<0.001), with a less severe renal involvement
or a minor risk of death, and, in one tested patient, with a novel poi
nt mutation (TCGA--> TCAA) at the enhancer-promoter region of the AAT
gene. Low AAT serum levels did not correlate with either type/titre of
autoantibody or distribution/severity of the vasculitis process. In t
he case-control study, high AAT levels emerged as a major determinant
of progression towards end-stage renal failure [odds ratio 3 (95% CI 1
.1-8.4)]. These results indicate: (a) a high incidence of the PiZ gene
of AAT in systemic vasculitis irrespective of the type of autoantibod
ies; (b) a novel form of AAT deficiency associated with the normal PiM
phenotype becoming manifest only during acute illness; (c) dysregulat
ion of the acute-phase response affecting selectively AAT or both AAT
and PCR; (d) correlation between low plasma levels of AAT and less sev
ere renal involvement or risk of death.